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ERLUX assay
T47D-Kbluc cells were routinely grown in growth media (GM) consisting of RPMI (L-glutamine free), which contained glucose (2.5 g/L; Sigma Aldrich), HEPES (10 mM), sodium pyruvate (1 mM; Sigma Aldrich), insulin (0.2 U/mL), 10% foetal bovine serum (FBS), penicillin (100 U/mL), streptomycin (100 μg/mL), and L-glutamine (2 mM). Briefly, T47D-KBluc cells were transferred into a low-estrogen condition by using pre-assay media (PAM; identical to GM, but 10% carcoldextran stripped FBS, no antibiotics) one week prior to testing. 10 000 cells/well in PAM were seeded into white, sterile, 96-well plates with lids (Greiner BIO-ONE Ltd.). Over the next 24 h the cells were allowed to attach. PAM was then removed from the plate and the samples, positive controls (E2, genistein), and solvent control (0.5% DMSO) were applied in dosing media (DM; phenol-red free RPMI, 5% carcol-dextran stripped FBS, no antibiotics). Eight replicates of solvent controls plus an antiestrogen, fulvestrant (1 μM), and eight replicates of the positive control plus fulvestrant (1 μM), were used to monitor the background estrogenicity in each assay.
The performance of the assay was considered to be satisfactory when the antiestrogen sufficiently blocked the estrogenic effect of the positive control.
Cytotoxicity assessment in the ERLUX assay
40 000 cells/well were seeded and incubated as described for the ERLUX assay and 24 h after the application of the treatment, the DM was gently removed and replaced by 100 L DM and an additional 20 L of MTT solution (5 mg/mL in HBSS) per well. Cells were incubated for 4 h and lysed afterwards with 150 L of a mixture consisting of 250 mL dimethylformamide, 250 mL deionised H 2 O, 100 g sodium dodecyl sulphate, 10 mL glacial acetic acid, and 5 mL hydrochloric acid (2 M). The solubilisation solution was adjusted to pH 4.7 [1] . The optical density of the formazan was quantified at 570 nm (Labsystem Multiscan). 40 000 cells/well was chosen for the cytotoxicity testing, as the original number of 10 000 cells/well was too low to observe mitochondrial activity by the formation of purple coloured formazan. The results of the cytotoxicity assay were normalised by subtraction of the background absorbance of the DM (100 L), the MTT solution (20 L), and 40 000 cells (blank wells). The normalised raw data were then divided by the average of on-plate solvent controls (n = 8) and multiplied by 100, to express the results as % of viable cells compared to solvent controls.
Modification of the SSRI assay
The cells (100 000 cells/well) were seeded into poly-D-lysine (50 mg/mL) coated 24-well plates (Nunc, Thermo Scientific) and allowed to attach for 48 h at 37 C (5% CO 2 , humidified incubator). The medium was removed and wells were washed with 200 L wash-Krebs-RingerHepes-buffer [wash-KRH, 120 mM NaCl, 4.7 mM KCl, 2.2 mM Ca 2 Cl, 10 mM Hepes, 1.2 mM KH 2 PO 4 , 1.2 mM MgSO 4 , endotoxin-free water (cell culture grade)]. Test samples were diluted with assay KRH identical to wash-KRH except for the addition of D-glucose (10 mM), ascorbic acid (100 M), and paragyline (100 M). The highest DMSO concentration in the wells was 1%.
The test sample in the assay-KRH solution was applied (500 L/well) and cells were incubated for 10 min at 37 C, before 5-HT solution (20.5 pmoles 5-HT and 0.1 pmoles [
3 H]-5-HT) was added to each well. Plates were incubated for a further 10 min and washed with ice-cold wash-KRH (3) before the cells were solubilised in 0.1% NaOH.
Modification of the AChEI assay
Briefly, 25 L Tris buffer (50 mM, pH 8) was added to all test wells (duplicate columns of 6 wells/sample). 25 L of test solution were added to the first wells of the columns and by removing 25 L from those wells and adding them to the next column; a 1:2 serial dilution was MHz).
Fig. 8S
The HMQC spectrum of luteolin-7-O-glucuronide (DMSO-d 6 , 500 MHz).
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Fig. 10S
The HMBC spectrum of luteolin-7-O-glucuronide (DMSO-d 6 , 500 MHz).
Fig. 11S
The (+)-HR-ESI-MS spectrum of luteolin-7-O-glucuronide.
Fig. 12S
1 H-NMR spectrum of fraction 7.6.7.6 (bottom) and luteolin-7-O-glucoside (DMSO-d 6 , 500 MHz).
